TomoTherapy and Hitachi Medical Corporation Enter Into Distribution Agreement for Japan

MADISON, Wis.--(BUSINESS WIRE)--TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has entered into an exclusive agreement with Hitachi Medical Corporation (HMC) to distribute the Hi·Art® cancer treatment system in Japan. Through the agreement, HMC will market, sell and service the innovative Hi·Art system, which facilitates highly precise, CT-guided radiation therapy for a wide range of clinical indications.

MORE ON THIS TOPIC